Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18579086 | 1.00 | ACE (0.84) | ACELMNAF2F10SMN1; SMN2 | |
| SCHEMBL682331 | 1.00 | ACE (0.84) | ACELMNAF2F10SMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL18712916 | 0.92 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL156900 | 0.92 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL15680 | 0.92 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL24062681 | 0.92 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL7276347 | 0.92 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL649165 | 0.92 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL7268245 | 0.92 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Lisinopril Anhydrous SCHEMBL13575800 | 0.92 | ACE (1.00) | ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0463636-A2 | Cardiovascular composition | MERCK FROSST CANADA INC. (CA) | 1992-01-02 | — | — | EP | claimed |
| EP-0129136-B1 | ANTIHYPERTENSIVE COMPOSITION | MERCK & CO. INC. (US) | 1991-10-30 | — | — | EP | claimed |
| EP-0168769-A2 | Process for preparing carboxyalkyl dipeptides | MERCK & CO. INC. (US) | 1986-01-22 | — | — | EP | claimed |
| EP-0166257-A2 | Cardiovascular composition | MERCK FROSST CANADA INC. (CA) | 1986-01-02 | — | — | EP | claimed |
| EP-0129136-A2 | Antihypertensive composition | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| US-4472384-A | INTERPHENYLENE 9-THIA-11-OXO-12-AZA PROSTANOIC ACID DERIVATIVE AND CARBOXYALKYLDIPEPTIDE | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| EP-0079521-A1 | Process for preparation of carboxyalkyldipeptide derivatives | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | claimed |
| US-4374829-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-02-22 | — | — | US | claimed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | claimed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-5081145-A | Contractile prostaglandin antagonists | MERCK FROSST CANADA, INC. (CA) | 1992-01-14 | — | — | US | disclosed |
| EP-0463636-A2 | Cardiovascular composition | MERCK FROSST CANADA INC. (CA) | 1992-01-02 | — | — | EP | disclosed |
| EP-0129136-B1 | ANTIHYPERTENSIVE COMPOSITION | MERCK & CO. INC. (US) | 1991-10-30 | — | — | EP | disclosed |
| EP-0166591-B1 | INDOLE-2-ALKANOIC ACIDS AND THEIR USE AS PROSTAGLANDIN ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1989-11-23 | — | — | EP | disclosed |
| EP-0140784-A2 | Prostaglandin antagonists | MERCK FROSST CANADA INC. (CA) | 1985-05-08 | — | — | EP | disclosed |
| EP-0129136-A2 | Antihypertensive composition | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | disclosed |
| US-4472384-A | INTERPHENYLENE 9-THIA-11-OXO-12-AZA PROSTANOIC ACID DERIVATIVE AND CARBOXYALKYLDIPEPTIDE | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | disclosed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | disclosed |
| EP-0079521-A1 | Process for preparation of carboxyalkyldipeptide derivatives | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | disclosed |
| US-4374829-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | ACE 114/4885LMNA 1841/4885F2 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.